Increased levels of interleukin-6 or transforming growth factor-β related to skeletal muscle atrophy contributed to poor treatment response in malignant melanoma, non-small cell lung cancer, and urothelial cancer treated with ICB (24, 27, 28). This evidence concerns the gene IL6 and melanoma.